ArticleThorax2016
Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.
Article in Thorax, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03643302 (Clinical Efficacy and Safety of Tran-bronchoscopy Airway Clearance and Bronchoalveolar Lavage in the Treatment of Moderate to Severe Bronchiectasis With Acute Exacerbation), which is not on this map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy and Safety of Tran-bronchoscopy Airway Clearance and Bronchoalveolar Lavage in the Treatment of Moderate to Severe Bronchiectasis With Acute Exacerbation
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Pooled it
- Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis.Bioscience reports · 2020Pooled it
- Trial
- Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial.BMC pulmonary medicine · 2019Trial
- An interpretable prognostic model for early unfavorable outcomes after bronchiectasis surgery.BMC pulmonary medicine · 2026Article
- Microbiological Analysis Following Periodontal Treatment in Individuals with Bronchiectasis.Microorganisms · 2026Article
- Body Composition and Muscle Function in Bronchiectasis: A Comparative Longitudinal Study.Respirology (Carlton, Vic.) · 2026Article
- From evidence to practice: What the 2025 European Respiratory Society Bronchiectasis Guideline means for India.Lung India : official organ of Indian Chest Society · 2026Article
- Dual Bronchodilators in Bronchiectasis Study: a randomised controlled trial.ERJ open research · 2025Article
- Anxiety, depression, physical disease parameters and health-related quality of life in the BronchUK national bronchiectasis cohort.ERJ open research · 2025Article
- Disease Severity and Activity in Bronchiectasis: A Paradigm Shift in Bronchiectasis Management.Tuberculosis and respiratory diseases · 2025Article
- Case Report: successful treatment of severe bronchiectasis by inhalation of mesenchymal stem cell-derived exosomes.Frontiers in medicine · 2025Article
- The characteristics and prognosis of bronchiectasis patients with airflow limitation: a prospective longitudinal study.BMC pulmonary medicine · 2024Article
- The Association of Depression with Obstructive Sleep Apnea in Patients with Cystic and Non-Cystic Fibrosis Bronchiectasis.Life (Basel, Switzerland) · 2024Article
- Bronchiectasis in Asia: a review of current status and challenges.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Potential New Inflammatory Markers in Bronchiectasis: A Literature Review.Current issues in molecular biology · 2024Review
- Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).The European respiratory journal · 2024Observational
- Bronchiectasis in Türkiye: Data from a Multicenter Registry (Turkish Adult Bronchiectasis Database).Balkan medical journal · 2024Article
- Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).The European respiratory journal · 2024Observational
- Applicability and Validity of the "Bronchiectasis Severity Index" (BSI) and "FACED" Score in Adult Aboriginal Australians.International journal of chronic obstructive pulmonary disease · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 7 countries.
Funding
Abstract
introductionBronchiectasis is a multidimensional disease associated with substantial morbidity and mortality. Two disease-specific clinical prediction tools have been developed, the Bronchiectasis Severity Index (BSI) and the FACED score, both of which stratify patients into severity risk categories to predict the probability of mortality.
methodsWe aimed to compare the predictive utility of BSI and FACED in assessing clinically relevant disease outcomes across seven European cohorts independent of their original validation studies.
resultsThe combined cohorts totalled 1612. Pooled analysis showed that both scores had a good discriminatory predictive value for mortality (pooled area under the curve (AUC) 0.76, 95% CI 0.74 to 0.78 for both scores) with the BSI demonstrating a higher sensitivity (65% vs 28%) but lower specificity (70% vs 93%) compared with the FACED score. Calibration analysis suggested that the BSI performed consistently well across all cohorts, while FACED consistently overestimated mortality in 'severe' patients (pooled OR 0.33 (0.23 to 0.48), p<0.0001). The BSI accurately predicted hospitalisations (pooled AUC 0.82, 95% CI 0.78 to 0.84), exacerbations, quality of life (QoL) and respiratory symptoms across all risk categories. FACED had poor discrimination for hospital admissions (pooled AUC 0.65, 95% CI 0.63 to 0.67) with low sensitivity at 16% and did not consistently predict future risk of exacerbations, QoL or respiratory symptoms. No association was observed with FACED and 6 min walk distance (6MWD) or lung function decline.
conclusionThe BSI accurately predicts mortality, hospital admissions, exacerbations, QoL, respiratory symptoms, 6MWD and lung function decline in bronchiectasis, providing a clinically relevant evaluation of disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.